- Home
- AVIR vs CYRX Comparison
AVIR vs CYRX Comparison
Compare AVIR & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | CYRX |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.9M | 419.3M |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | AVIR | CYRX |
|---|---|---|
| Price | $5.94 | $9.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $8.00 | ★ $12.94 |
| AVG Volume (30 Days) | ★ 475.6K | 401.1K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.00 | ★ 156.22 |
| EPS | N/A | ★ 1.40 |
| Revenue | ★ $351,367,000.00 | $176,177,000.00 |
| Revenue This Year | N/A | $11.06 |
| Revenue Next Year | N/A | $8.45 |
| P/E Ratio | ★ N/A | $6.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.46 | $5.01 |
| 52 Week High | $6.45 | $11.45 |
Technical Indicators
Market Signals| Indicator | AVIR | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.91 | 63.78 |
| Support Level | $3.33 | $9.18 |
| Resistance Level | $6.45 | $9.32 |
| Average True Range (ATR) | 0.29 | 0.42 |
| MACD | -0.00 | 0.17 |
| Stochastic Oscillator | 73.63 | 76.77 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About CYRX CryoPort Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.